Prediction of the Development of Osteoarthritis of the Hip Joint Based on Distribution of the Gene Encoding 5-Factor Gdf5 Growth Differentiations

Shodikulova G.Z.; Khasanov O.G.; Tairova Z.K.

Shodikulova G.Z. 1. Head of the Department of Internal Medicine No. 3 of the Samarkand State Medical University, Professor
Khasanov O.G. PhD student in “Internal Medicine” of the Samarkand State Medical University
Tairova Z.K. Assistant of the Department of Internal Medicine No. 3 of the Samarkand State Medical University

Keywords: Idiopathic osteoarthritis, post-COVID osteoarthritis, genetic marker, genotype

Abstract

Medical research confirms that inherited genetic tendencies strongly increase coxarthrosis development as a degenerative disease mainly targeting the hip joint. Searchers have determined Single Nucleotide Polymorphisms (SNPs) as major genetic elements that help initiate this disease process. Research findings show that SNPs act as direct contributors to coxarthrosis development by actively affecting the disease pathogenesis in addition to being non-random associations. SNPs have a substantial effect on cellular and molecular mechanisms which control the structural well-being and operational competence of articular cartilage together with subchondral bone. Genetic studies show SNPs enable control over signaling pathway and metabolic processes including those concerning extracellular matrix (ECM) and chondrocytes and osteocytes. The pathways control essential processes which include collagen production along with proteoglycan regulation and mechanical pressure and inflammatory response of cells. The abnormalities triggered by particular polymorphisms create problems with ECM remodeling alongside enhanced cartilage breakdown while producing bone structural modifications that are core elements of coxarthrosis. The deterioration of joint tissue caused by abnormal signaling between chondrocytes and osteocytes becomes worse because of SNP-related signaling dysfunctions. Research on genetic variants helps explain coxarthrosis origin while creating individualization strategies for both diagnostics and disease monitoring procedures and therapeutic options for reducing its progression.

References

[1] S. G. Zikriyaevna and T. Z. Kamolidinovna, “Stratification of Cardiovascular Risk in Patients with Rheumatoid Arthritis,” Telematique, vol. 22, no. 01, pp. 1114–1119, 2023.
[2] L. Q. Zhu et al., “Whole genome sequencing of pairwise human subjects reveals DNA mutations specific to developmental dysplasia of the hip,” Genomics, vol. 111, no. 3, pp. 320–326, 2019, doi: 10.1016/j.ygeno.2018.02.006.
[3] W. Zhou, W. Luo, D. Liu, F. Canavese, L. Li, and Q. Zhao, “Fluoride increases the susceptibility of developmental dysplasia of the hip via increasing capsular laxity triggered by cell apoptosis and oxidative stress in vivo and in vitro,” Ecotoxicol Env. Saf, vol. 234, p. 113408, 2022, doi: 10.1016/j.ecoenv.2022.113408.
[4] G. Z. Shodikulova, U. S. Pulatov, and O. G. Khasanov, “The state of the peripheral blood system of patients with rheumatoid arthritis depending on haptoglobin polymorphism,” J. Cardiorespir. Res., vol. 1, no. 1, 2023.
[5] X. Zhao, S. Liu, Z. Yang, and Y. Li, “Molecular mechanisms and genetic factors contributing to the developmental dysplasia of the hip,” Front Genet, vol. 15, p. 1413500, 2024, doi: 10.3389/fgene.2024.1413500.
[6] D. Li and others, “Inflammatory and fibrosis infiltration in synovium associated with the progression in developmental dysplasia of the hip,” Mol Med Rep, vol. 19, no. 4, pp. 2808–2816, 2019, doi: 10.3892/mmr.2019.9910.
[7] A. M. Kiapour, J. Cao, M. Young, and T. D. Capellini, “The role of Gdf5 regulatory regions in the development of hip morphology,” PLoS One, vol. 13, no. 11, p. e0202785, 2018, doi: 10.1371/journal.pone.0202785.
[8] E. Kenanidis, N. K. Gkekas, A. Karasmani, P. Anagnostis, P. Christofilopoulos, and E. Tsiridis, “Genetic predisposition to developmental dysplasia of the hip,” J Arthroplasty, vol. 35, pp. 291–300, 2020.
[9] T. Z. Kamolidinovna and S. G. Zikriyaevna, “Risk Factors and Features of Coronary Heart Disease in Patients with Rheumatoid Arthritis,” J. Biomed. Pract., vol. 7, no. 6, 2022.
[10] M. L. Genovesi and others, “GDF5 mutation case report and a systematic review of molecular and clinical spectrum: expanding current knowledge on genotype-phenotype correlations,” Bone, vol. 144, p. 115803, 2021, doi: 10.1016/j.bone.2020.115803.
[11] N. T. Doncheva et al., “Human pathways in animal models: possibilities and limitations,” Nucleic Acids Res, vol. 49, no. 4, pp. 1859–1871, 2021, doi: 10.1093/nar/gkab012.
[12] R. Ding et al., “Downregulation of miR-1-3p expression inhibits the hypertrophy and mineralization of chondrocytes in DDH,” J Orthop Surg, 2021.
[13] R. Chijimatsu and T. Saito, “Mechanisms of synovial joint and articular cartilage development,” Cell Mol Life Sci, vol. 76, no. 20, pp. 3939–3952, 2019, doi: 10.1007/s00018-019-03191-5.
[14] J. Chen and others, “Developmental dysplasia of the hip: a special pathology,” Chin J Traumatol, vol. 21, no. 4, pp. 238–242, 2018, doi: 10.1016/j.cjtee.2018.02.001.
[15] A. Ragaban, L. Alsharif, N. A. Alshaikh, and et al, “Prevalence, etiology, risk factors, and complications of facial nerve palsy at King Abdulaziz Medical City: a multicenter study,” Cureus, vol. 16, p. 0, 2024, doi: 10.7759/cureus.53403.